Note 15- Segments (Tables)

12 Months Ended

Dec. 31, 2021

Year Ended December 31, 2021	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	—		$	—		$	—		$	—
License revenue		45,615			—			—			45,615
Grant and other revenue		485,898			—			—			485,898
Total revenue		531,513			—			—			531,513
Research and development expenses, excluding depreciation and amortization		4,488,177			653,733			—			5,141,910
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾		—			4,438			7,368,623			7,373,061
Depreciation and amortization ⁽²⁾		24,162			—			52,792			76,954
Loss from operations ⁽³⁾		(3,980,826	)		(658,171	)		(7,421,415	)		(12,060,412	)
Other income ⁽⁴⁾		—			—			345,524			345,524
Provision for income taxes		(5,452	)		(901	)		(9,690	)		(16,043	)
Net loss		(3,986,278	)		(659,072	)		(7,085,581	)		(11,730,931	)
Total assets, net of depreciation and amortization:
United States	$	107,931		$	—		$	6,326,031		$	6,433,962
International		210,281			—			590			210,871
Capital expenditures		—			—			25,218			25,218

Year Ended December 31, 2020	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	7,995		$	—		$	—		$	7,995
License revenue		110,730			—			—			110,730
Grant and other revenue		482,221			314,067			—			796,288
Total revenue		600,946			314,067			—			915,013
Cost of revenue		1,048			—			—			1,048
Research and development expenses		4,593,459			336,728			—			4,930,187
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾		299,959			800			6,323,807			6,624,566
Depreciation and amortization ⁽²⁾		10,068			—			60,325			70,393
Loss from operations ⁽³⁾		(4,303,588	)		(23,461	)		(6,384,132	)		(10,711,181	)
Other expense ⁽⁴⁾		—			—			(10,510	)		(10,510	)
Net loss		(4,303,588	)		(23,461	)		(6,394,642	)		(10,721,691	)
Total assets, net of depreciation and amortization:
United States	$	139,121		$	—		$	7,416,106		$	7,555,227
International		202,791			—			—			202,791
Capital expenditures		120,810			—			15,071			135,881